CoV2Research - May2020 - 16

Serological Study of COVID-19
Better tools designed for high-throughput serosurveillance studies
of COVID-19 and other respiratory infections.

from 8 PCR-confirmed COVID-19 patients and from
144 negative control sera collected prior to the pandemic. The results demonstrate a distinct antibody
profile for SARS-CoV-2 in confirmed COVID-19 patients but a comparable antibody profile for common cold coronavirus between the two groups. This
study highlights the potential of antigen array as a
serosurveillance solution in epidemiologic studies
of COVID-19.

SinommuneTM: CoVAM Coronavirus
Antigen Array
Sino Biological cooperates with Nanommune Inc.,
an Irvine, California, based biotechnology company specializing in the development and application
of multiplex array technology to develop coronavirus antigen array products for serological studies
of COVID-19 and other infectious diseases. Sino
Biological and Nanommune debuted the first product on April 22 under Sino Biological's new brand,
Sinommune™.

"We are extremely pleased with the performance
of the Sinommune array product and believe this
platform will serve as a foundational tool for serological studies in the global fight against COVID-19,"
said Dr. Philip Felgner, Director of the Vaccine R&D
Center at UCI Medical School. "In order for communities around the globe to understand the prevalence
and threat posed by COVID-19, a comprehensive

In a recent joint study published on Biorxiv, researchers from UCI, Cerus, University of Maryland, Oregon
Health and Science University, and the Vitalant
Research Institute used this array to characterize the
antibody profile of convalescent blood specimens

16
CoV2Research - May2020

Table of Contents for the Digital Edition of CoV2Research - May2020
